ERBB2 and neoplasm: Despite low and heterogeneous ErbB2 expression levels, we confirmed sufficient and ErbB2-specific antitumor capacity of NK-92/5.28.z cells against both, r/r 2D patient-derived tumor organoid RMS cells and 3D RMS tumor spheroid models.